Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists

This invention relates to phenyl-oxo-tetrahydroquinolin-3-yl 3 adrenergic receptor agonists useful for the treatment of metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenic inflammation, glaucoma, ocular hypertension, frequent urination; and are particularly useful in the treatment or inhibition of type 11 diabetes. This invention provides compounds of Formula I having the structure and X are as defined hereinbefore,or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.